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Abstract
Background: The definition of human MHC class I haplotypes through association of HLA-A,
H L A - C w  a n d  H L A - B  h a s  b e e n  u s e d  t o  a n a l y z e  ethnicity, population migrations and disease
association.
Results:  Here, we present HLA-E allele haplotype association and population linkage
disequilibrium (LD) analysis within the ~1.3 Mb bounded by HLA-B/Cw and HLA-A to increase the
resolution of identified class I haplotypes. Through local breakdown of LD, we inferred ancestral
recombination points both upstream and downstream of HLA-E contributing to alternative block
structures within previously identified haplotypes. Through single nucleotide polymorphism (SNP)
analysis of the MHC region, we also confirmed the essential genetic fixity, previously inferred by
MHC allele analysis, of three conserved extended haplotypes (CEHs), and we demonstrated that
commercially-available SNP analysis can be used in the MHC to help define CEHs and CEH
fragments.
Conclusion: We conclude that to generate high-resolution maps for relating MHC haplotypes to
disease susceptibility, both SNP and MHC allele analysis must be conducted as complementary
techniques.
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Background
The human major histocompatibility complex (MHC) is
a highly polymorphic genomic region occupying approx-
imately 4 Mb on chromosome 6p21.3. In addition to the
major HLA class I and class II gene clusters, there are sev-
eral other HLA-related and immune response-related
genes, some of unknown function, as well as likely pseu-
dogenes. The rich polymorphism in this region is a critical
determinant for success in tissue transplantation, and in
recent years has found a further use in characterizing both
ethnic and geographical population relationships. Haplo-
type analysis is based on the conservation of short blocks
of conserved DNA sequence containing specific allele
combinations of two or more adjacent or nearby genetic
loci. Within the MHC region, a limited number of specific
haplotypes are known to be shared by unrelated individ-
uals of well-defined human populations. These relatively
long stretches of conserved DNA sequence in the MHC
have been termed conserved extended haplotypes (CEHs)
[1] or ancestral haplotypes [2,3]. It is also well recognized
that CEHs may be represented as a higher order of associ-
ation, through successive generations, of four or more
defined MHC blocks, showing a stronger linkage disequi-
librium (LD) to that expected by random recombination.
Portions of a few CEHs can be detected by maximum like-
lihood statistics but much more precisely and completely
by family studies and direct counting [1-6]. In either
instance, LD can be analyzed and a significance assigned
to the association [1-6]. MHC haplotype blocks and the
larger CEHs are usually inherited intact as a unit, and the
allele frequency distribution of particular MHC locus
combinations in individuals is non-random [1-7].
Reports describe the existence of blocks of conserved DNA
sequence in the range of 5 to 150 kb within the human
genome separated by sites of high recombination activity
[8-10]. These reports, based on LD analysis applied to sin-
gle nucleotide polymorphism (SNP) data, suggested the
blocks represent relatively uniform lengths of conserved
DNA sequence maintained throughout the human popu-
lation as haplotypes.
Conserved MHC blocks and CEHs have been shown to
represent markers of human diversity and/or disease sus-
ceptibility [4]. Multi-block conserved haplotypes are not
limited to the MHC region since genes encoding drug
metabolizing enzymes [11], hormone receptors [12] or
microtubule-associated proteins [13] are also associated
with extended haplotype blocks. For human MHC stud-
ies, past work has focused on haplotypes defined by the
relationship of classical HLA class I and class II loci and
intermediate MHC genes. The HLA-E  locus, located
approximately halfway between the HLA-A and Cw class I
loci approximately 780 kb telomeric to HLA-C, has lim-
ited polymorphism and has not generally been incorpo-
rated into HLA association studies. Here, we describe
newly identified block associations within the MHC, spe-
cifically determining the distribution of HLA-E alleles in
relation to HLA-A, B, Cw, complotype and DRB1 blocks,
defining a set of CEHs extending over 2.6 Mb (1.5% of
chromosome 6). The inclusion of HLA-E in MHC haplo-
type analysis significantly improves the resolution of class
I haplotypic blocks, further refining our ability to analyze
associations of the human MHC to disease. Through SNP
analysis of the MHC class I/class II region, we confirmed
the regional genetic fixity identified by MHC allele analy-
sis and demonstrated that SNPs can be used in the MHC
to help define CEHs and CEH fragments.
Results
To improve human MHC haplotype resolution, we ini-
tially set about determining HLA-E allele polymorphism
in the HLA-A/HLA-Cw interval. Within our samples, only
4 of the currently-identified HLA-E alleles were identified
(E*0101,  E*010301,  E*010302  and  E*010303) while
HLA-E*0104 was not detected. We did not type for the
recently identified allele HLA-E*010304 [14]; our typing
method would have designated such an allele, if it existed
in our subjects, as HLA-E*010302.  HLA-E*010303  was
found in only one of 176 individuals screened (represent-
ing subjects from all 3 panels studied) and was therefore
not tested for in the other subjects, but frequent alleles
found were HLA-E*0101, followed by E*010302  and
E*010301 in 583 individuals. HLA-A, Cw and B alleles
were identified at expected frequencies for Caucasian,
African-American and Hispanic populations, respectively
[1]. In 216 individuals (Panel 1), we found 9 statistically
significant haplotypes between HLA-A and HLA-Cw, B,
only 5 between HLA-E  and HLA-Cw/B and 7 between
HLA-A and HLA-E (Table 1). Of the latter, the two most
significant were (A*0101,  E*0101) and (A*0301,
E*010302). Of the 5 identified associations between HLA-
E  and HLA-Cw/B, the most significant were (E*0101,
Cw*0701, B*0801) and (E*010302, Cw*0702, B*0702).
Analysis of the entire class I region revealed 9 haplotypes,
of which the most significant were (A*0101,  E*0101,
Cw*0701,  B*0801); (A*0301,  E*010302,  Cw*0702,
B*0702) and (A*0201, E*0101, Cw*0501, B*4402).
Many significant HLA-Cw/B associations were found
within Panel 2, as expected due to the physical proximity
of HLA-Cw and -B (85 kb). Extending the region to 864 kb
between HLA-E and HLA-B, 4 of the same HLA class I hap-
lotypes found in Panel 1 individuals and 4 other statisti-
cally significant class I haplotypes were found (Fig. 1,
column C). LD analysis of the complete class I region
encompassing 1.41 Mb identified the same 9 class I hap-
lotypes found in Panel 1 (Fig. 1, column D). All four HLA-
A/E pairs in LD (Fig. 1, column B) were part of at least one
of the larger class I haplotypes (gray lines). However,BMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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some of the larger haplotypes contained sub-domain
regions not strongly linked when analyzed independ-
ently. Specifically, 4 HLA-A/E pairs ((A*0201, E*0101);
(A*2301,  E*0101); (A*2402,  E*0101) and (A*0201,
E*010302)) found in the larger class I haplotypes (Fig. 1,
red lines) did not show significant LD when analyzed
alone. Analysis of HLA-E to Cw/B (Fig. 1, column C)
revealed that HLA-E*0101 was not in LD with (Cw*0401,
B*3501); (Cw*0602,  B*5701) nor (Cw*0401,  B*4403)
despite significant LD when the haplotypes included
HLA-A  (Fig 1, Column D). Conversely, one haplotype
with strong D', (E*010301, Cw*12xx, B*5201), was not in
LD with HLA-A. From these results, we infer ancestral
breakpoints both centromeric and telomeric to HLA-E.
Within Panel 3, we also studied CEHs, ranging over 2.6
Mb, consisting of their HLA class I loci (Table 2) along
with the class II HLA-DRB1 locus and the closely-linked
complement genes BF, C2, C4A and C4B (the complo-
type; Table 3). HLA-E alleles were found to be in signifi-
cant association with 10 CEHs (Table 3), but excluding
HLA-A reduced this number. Nevertheless, HLA-E associ-
ation with the Cw/B block and HLA-A in Panel 3 (Table 2)
showed significance for 7 of the 9 class I haplotypes
observed in Panels 1 and 2. Furthermore, 6 other class I
haplotypes not found in Panels 1 or 2 had statistical sig-
nificance in Panel 3.
Inclusion of HLA-E improved the definition of CEH class
I fragments. For example, HLA-E*0101 was a marker for
the CEHs [HLA-A*01,  Cw*07,  B*08,  SC01,  DRB1*07],
[HLA-A*30, Cw*06, B*13, SC31, DRB1*07], [HLA-A*25,
Cw*12, B*18, S042, DRB1*15] and [HLA-A*01, Cw*06,
B*57, SC61, DRB1*07]. Likewise, HLA-E*010301 was a
marker for the CEH [HLA-A*26,  Cw*12,  B*38,  SC21,
DRB1*04] and HLA-E*010302 was a marker for the CEH
[HLA-A*30,  Cw*05,  B*18,  F1C30,  DRB1*03]. Further-
more, HLA-E could distinguish class I haplotype variants
of at least one CEH: in the two most frequent class I vari-
ants of the CEH [HLA-Cw*07, B*07, SC31, DRB1*15],
HLA-A*02 was associated with HLA-E*0101 while HLA-
A*03  was associated with HLA-E*010302. Finally, we
found HLA-E to be an additional class I locus able to dif-
ferentiate two HLA-B*4403 CEH variants: [HLA-A*2902,
E*010302,  Cw*1601,  B*4403,  FC31,  DRB1*07] and
[HLA-A*2301,  E*0101,  Cw*04xx,  B*4403,  FC31,
DRB1*07].
Panel 3 provided further evidence of ancient recombina-
tion within the HLA class I region both centromeric and
telomeric to HLA-E. The two HLA-A, E variants of the CEH
[HLA-Cw*07, B*07, SC31, DRB1*1501] strongly suggest a
past recombination event between HLA-E  and  HLA-C.
Conversely, the larger number of (HLA-E*0101, Cw*08,
B*14) and HLA-E*0101, Cw*06, B*50) haplotypes found
as compared with their most frequent HLA-A variants
implies past recombination events between HLA-E and
HLA-A. In summary, we demonstrate, by both χ2 and LD
analysis, non-random association of HLA-E alleles with
alleles at other class I loci and the HLA-E allele markers for
10 CEHs. Through breakdown of LD between MHC
blocks, we once again infer recombination breakpoints on
Table 1: Statistical analysis of HLA-A, -E, -Cw and -B haplotypes for Panel 1.
II I I I I
HLA-A* HLA-E* f1 P2 HLA-E* HLA-Cw*/B* f1 P2 HLA-A* HLA-E* HLA-Cw*/B* f1 P2
0101 0101 95/432 < 1 × 10-7 0101 0701, 0801 51/432 1.2 × 10-6 0101 0101 0701, 0801 42/432 < 1 × 10-7
0602, 5701 14/432 ns 0602, 5701 10/432 5 × 10-6
0101 39/432 ns 0101 0501, 4402 13/432 ns 0101 0501, 4402 12/432 < 1 × 10-7
0201 07XX, 4402 16/432 ns 0201 07xx, 4402 6/432 ns
010302 28/432 0.0138 010302 03xx, 40xx 10/432 0.006 010302 03xx, 40xx 7/432 0.0001
0301 010302 30/432 3 × 10-7 010302 0702, 0702 32/432 < 1 × 10-7 0301 010302 0702, 0702 21/432 < 1 × 10-7
010301 13/432 0.00213
1101 0101 20/432 ns 0101 0401, 3501 36/432 ns 0101 0101 0401, 3501 6/432 ns
010301 8/432 0.025 010301 0602, 13XX 6/432 0.0005 010301 0602, 13xx 3/432 ns
2301 0101 9/432 ns 0101 08xx, 14xx 11/432 ns 2301 0101 08xx, 14xx 1/432 ns
0401, 4403 3/432 ns 0401, 4403 2/432 0.0154
2402 0101 31/432 ns 0101 0401, 3501 36/432 ns 2402 0101 0401, 3501 13/432 0.0008
010301 8/432 ns 010301 12xx, 5201 2/432 ns 010301 12xx, 5201 2/432 ns
24xx 010302 16/432 ns 010302 03xx, 15xx 9/432 ns 24xx 010302 03xx, 15xx 4/432 ns
2601 010301 4/432 0.022 010301 1203, 3801 4/432 0.012 2601 010301 1203, 3801 4/432 2 × 10-6
2902 010302 4/432 ns 010302 1601, 4403 3/432 ns 2902 010302 1601, 4403 2/432 0.005
3001 010302 2/432 ns 010302 0501, 1801 2/432 ns 3001 010302 0501, 1801 1/432 ns
68xx 010302 14/432 0.0183
1Frequency (f)
2Probability (p)
Not significant (ns)BMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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either side of HLA-E. Further, extension of the analysis
from HLA-A  to HLA-DRB1  increases the size of allele-
defined CEHs up to 2.6 Mb.
LD analysis of SNP databases derived from the general
population has gained widespread credibility as an alter-
native means for tracing evolutionary human genetic net-
works [8]. Within the human MHC spanning ~4.5 Mb,
the frequency distribution of identified SNPs (71,136
deposited in NCBI dbSNP Build 126) is highly non-uni-
form where regions with peaks represent regions of highly
polymorphic HLA-associated genes (Fig. 2A, upper
panel). The currently available gene mapping chips sam-
ple 500,000 SNPs for whole genome mapping with only
428 SNPs within the MHC region (Fig. 2A, lower panel).
This limited sampling (0.6%) is further affected by the
non-uniform representation of SNPs on screening arrays
where the defined HLA genes are under-represented
(because sampling has no significance unless the selected
SNPs are to be screened within a preselected limited set of
haplotypes). Accordingly, gene array SNPs tend to exclude
the highly polymorphic HLA class I and class II regions.
CEHs and genetic fixity, however, have been defined by
alleles of the coding genes. We therefore used SNP analy-
sis to study the co-segregation implied by locus allele
analysis.
A comparison of SNPs in cell lines homozygous for major
HLA loci was performed. Except for HLA-E, where the
EM10 cell line is heterozygous for HLA-E*0101 and HLA-
E*010301, EM10 and FS10 are homozygous for the CEH
[HLA-A*2601,  E*010301,  Cw*1203,  B*3801,  SC21,
Linkage disequilibrium (LD) analysis for haplotypes across the human class I region on chromosome 6 Figure 1
Linkage disequilibrium (LD) analysis for haplotypes across the human class I region on chromosome 6. Column A 
depicts individual alleles detected and analyzed within the Panel 2 subjects. The horizontal scale to the right of column A 
presents normalized LD (D') between 2 loci (HLA-A and HLA-E, and HLA-C and HLA-B, respectively). To the right of each D' 
value (), the relevant paired loci with significant association (P < 0.005 in bold color; P < 0.05 in weaker color) are depicted 
(column B). To the right of column B, the horizontal D' scale depicts the association () between HLA-E and paired HLA-Cw/
HLA-B alleles, with the associated alleles listed in column C where strong significant associations (P < 0.005 to < 0.00002) are 
listed in bold color, weaker associations (P < 0.05) in intermediate color, and non-significant associations indicated by lightest 
color. To the right of column C, the horizontal D' scale depicts the association () between HLA-A, -E, -Cw and -B representing 
HLA class I haplotypes over 1.4 Mb, where the associated alleles are listed in column D (P < 0.0001 in bold, P < 0.002 in inter-
mediate, and P < 0.05 in weak colors). The red lines indicate HLA-A alleles which are not in LD with HLA-E upon 2 locus anal-
ysis, but become significantly associated in the context of the 4 locus haplotypes including HLA-Cw/HLA-B.BMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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DRB1*0402,  DQA1*0301,  DQB1*0302] found at high
frequency in Ashkenazi Jews [4]. Over the entire MHC
region representing 369 individual SNPs which could be
reliably identified in both cell lines, only 5 instances of
heterozygosity in either cell line and only 2 instances of
complete discordance between the two cell lines were
detected (1.9%; Fig. 2B), thus supporting the block link-
age implied by our other gene analyses (Tables 1, 2, 3 and
Fig. 1). Further confirming our supposition concerning
the relationship between actual SNPs to those selected on
the chip array, the heterozygosity at the HLA-E locus of the
EM10 cell line was not detected by SNP analysis.
Similar SNP analysis of 2 cell lines (B8HM1 and B8HM2)
homozygous for the most frequent CEH in American and
British Caucasians [4] ([HLAA*0101, E*0101, Cw*0701,
B*0801, SC01, DRB1*0301, DQA1*0501, DQB1*0201])
revealed only 7 instances of heterozygosity and no
instances of complete discordance between the two cell
lines of 370 unambiguous SNPs analyzed (Fig. 2B).
Selecting only those SNPs identical in EM10 and FS10 and
designated "HLA-A*26, B*38", and comparing them with
those SNPs identical in B8HM1 and B8HM2 designated
"HLA-A*01,  B*08" (Fig. 2B), we observed 113/271
(41.7%) complete discordance between the two sets (p: <
Table 3: Haplotype statistical analysis for Panel 3, extending haplotypes into the complotype and HLA-DRB1 regions.
HLA-A* HLA-E* HLA-Cw*/B* Complotype HLA-DRB1* f1 P2 HLA-E* HLA-Cw*/B* Complotype HLA-DRB1* f1 P2
01 0101 07, 08 SC01 03 41/256 < 1 × 10-7 0101 07, 08 SC01 03 48/258 1 × 10-5
01 0101 06, 57 SC61 07 7/256 0.011 0101 06, 57 SC61 07 9/258 ns
02 0101 07,07 SC31 15 7/256 0.003 0101 07,07 SC31 15 8/258 ns
02 0101 05, 44 SC30 04 4/256 ns 0101 05, 44 SC30 04 4/258 ns
02 0101 06, 50 S1C2(1,17) 07 3/256 ns 0101 06, 50 S1C2(1,17) 07 4/258 ns
02 010302 03,15 SC33 04 2/256 ns 010302 03,15 SC33 04 2/258 ns
03 0101 06,47 FC91,0 07 2/256 ns 0101 06,47 FC91,0 07 2/258 ns
03 010302 07, 07 SC31 15 8/256 < 1 × 10-7 010302 07, 07 SC31 15 9/258 0.022
11 0101 04, 35 SC30 01 2/256 ns 0101 04, 35 SC30 01 4/258 ns
23 0101 04, 44 FC31 07 5/256 1.1 × 10-5 0101 04, 44 FC31 07 7/258 ns
24 0101 08, 14 SC2(1,2) 01 1/256 ns 0101 08, 14 SC2(1,2) 01 3/258 ns
25 0101 12, 18 S042 15 3/256 0.0007 0101 12, 18 S042 15 6/258 ns
26 010301 12, 38 SC21 04 9/256 < 1 × 10-7 010301 12, 38 SC21 04 9/258 < 1 × 10-7
29 010302 16, 44 FC31 07 11/256 < 1 × 10-7 010302 16, 44 FC31 07 11/258 1.2 × 10-5
30 0101 06, 13 SC31 07 4/256 0.0007 0101 06, 13 SC31 07 5/258 ns
30 010302 05,18 F1C30 03 10/256 < 1 × 10-7 010302 05,18 F1C30 03 12/258 0.0002
33 0101 03, 58 SC30 03 1/256 ns 0101 03, 58 SC30 03 2/258 ns
1Frequency (f)
2Probability (p)
Not significant (ns)
Table 2: Statistical analysis of HLA-A, -E, -Cw and -B haplotypes for Panel 3.
HLA-A* HLA-E* f p HLA-E* HLA-Cw*/B* f p HLA-A* HLA-E* HLA-Cw*/B* f p
01 0101 61/258 < 1 × 10-7 0101 07, 08 49/258 9 × 10-6 01 0101 07, 08 44/258 < 1 × 10-7
0101 06, 57 12/258 ns 01 0101 06, 57 10/258 5 × 10-5
02 0101 34/258 ns 0101 07, 07 10/258 ns 02 0101 07,07 7/258 0.007
0101 05, 44 9/258 ns 02 0101 05, 44 8/258 0.00013
0101 06, 50 6/258 ns 02 0101 06, 50 3/258 ns
02 010302 15/258 ns 010302 03,15 2/258 ns 02 010302 03,15 3/258 ns
03 0101 6/258 ns 0101 06, 47 2/258 ns 03 0101 06, 47 2/258 ns
03 010302 16/258 3 × 10-5 010302 07, 07 18/258 0.00046 03 010302 07, 07 14/258 < 1 × 10-7
11 0101 9/258 ns 0101 04, 35 7/258 ns 11 0101 04, 35 4/258 0.0006
23 0101 10/258 ns 0101 04, 44 9/258 ns 23 0101 04, 44 7/258 < 1 × 10-7
24 0101 10/258 ns 0101 08, 14 7/258 ns 23 0101 08, 14 1/258 ns
25 0101 5/258 ns 0101 12, 18 8/258 ns 25 0101 12, 18 5/258 < 1 × 10-7
26 010301 16/258 < 1 × 10-7 010301 12, 38 14/258 < 1 × 10-7 26 010301 12, 38 14/258 < 1 × 10-7
29 010302 17/258 9 × 10-7 010302 16, 44 16/258 < 1 × 10-7 29 010302 16, 44 16/258 < 1 × 10-7
30 0101 6/258 ns 0101 06, 13 5/258 ns 30 0101 06, 13 4/258 0.00063
30 010302 10/258 0.0261 010302 05,18 12/258 0.0002 30 010302 05,18 10/258 < 1 × 10-7
33 0101 4/258 ns 0101 03, 58 3/258 ns 33 0101 03, 58 2/258 0.009
1Frequency (f)
2Probability (p)
Not significant (ns)BMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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1 × 10-7). To demonstrate that the striking similarity of the
SNPs in EM10 as compared with FS10 and in B8HM1 as
compared with B8HM2 and that the striking difference
between the HLA-A*26, B*38 and HLA-A*01, B*08 SNPs
were not anomalies of the cell lines chosen, both sets of
SNPs were independently compared to those of another
cell line (L2DB), which is homozygous for a different
CEH ([HLA-A*0301, E*010302, Cw*0702, B*0702, SC31,
DRB1*1501,  DQA1*0102,  DQB1*0602]; designated
"HLA-A*03, B*07"). As shown in Fig. 2B, the HLA-A*03,
B*07 CEH SNPs differ significantly from those of either
the HLA-A*26, B*38 (31.25% complete discordance; p: <
1 × 10-7) or the HLA-A*01, B*08 (35.1% complete dis-
cordance; p: < 1 × 10-7) CEHs.
Discussion
Human MHC polymorphisms likely represent the geo-
graphic dispersal of early man and expansion of limited
haplotypes in concert with selection driven by local
microbial organisms. This has led to association of haplo-
types with both ethnicity and various immunopatholo-
gies. It has been postulated that the basis for some of the
disease-associations may be a cross-reactivity between a
microbe-specific peptide sequence and a closely-related
host sequence leading to anti-host reactivity (e.g., HLA-
B27 and ankylosing spondylitis [15]). To accurately iden-
tify the relationship of a genetic locus to disease, it is crit-
ical to determine whether an allele is associated with such
pathology or whether the locus is co-segregating due to
proximity with the responsible gene. Consideration of co-
segregation is particularly critical given that direct deter-
mination of MHC haplotypes from family studies shows
frequently occurring small block variants and given that a
third to a half of Caucasian haplotypes are fixed from
HLA-B to HLA-DRB1/DQB1 (at least 1 Mb) as CEHs [1-6].
To increase the resolution of haplotypes within the
human MHC region defined by population LD analysis,
this study was initially conceived as a means of incorpo-
rating HLA-E into the other class I, class II and complo-
type regions. HLA-E is an HLA-1b-type molecule of
limited polymorphism interacting with natural killer
receptors, functioning as an important mediator of cyto-
toxicity [16-18]. Initial LD analysis suggested that HLA-E
polymorphism occurred early in hominid development
and stabilized in Homo sapiens before the major geo-
graphic dispersals [19]. Consequently, it seems likely that
the distribution of HLA-E alleles represents population
migration with inbred expansion. In support of this
notion, our analysis of HLA-E alleles identified 3 alleles,
(HLA-E*0101, HLA-E*010301 and HLA-E*010302), non-
randomly associated with particular CEHs. Our typing
method was not designed to detect the recently identified
allele HLA-E*010304 [14], and, if it had been present in
any of the haplotypes, it would be reported here as HLA-
E*010302. We are unaware of any report describing the
population frequency of that allele; we shall clarify its
presence or absence in particular CEHs in future studies.
We identify apparent ancestral breakpoints upstream and
downstream of HLA-E, and in the context of the limited
number of HLA-E alleles identified, this would seem to
reinforce the notion of HLA-E polymorphism occurring
early in hominid development and stabilizing, and thus
not in conflict in any way with the more recent stabiliza-
tion of extended haplotypes confirmed here both by pop-
ulation LD analysis and SNP analysis. There is the further
implication that recombination breakpoints in the HLA
region are relatively infrequent.
Haplotype blocks and breakpoints revealed by popula-
tion analysis do not always correlate with those identified
by direct haplotype sequencing of sperm [20-22]. Sperm
crossover points may indicate the potential for recombi-
nation while family studies represent the practical end
result reflecting fertilization potential and environmental
selective pressures. Accordingly, recombination frequen-
cies from a single individual or limited pool should be
used cautiously to describe the effect of recombination on
haplotype frequencies in the population [6]. Other sug-
gested mechanisms to explain discrepancies between
sperm crossover points and family-inferred breakpoints
include higher crossover rates in female gametes not
observed in sperm [21], as well as the possibility that
some breakpoints recognized by segregation analysis rep-
resent inactive ancestral recombination "hot spots" which
have become fixed in populations [20].
Since selection in its most accepted formulation operates
mostly upon protein products, the power of allele variant
haplotype analysis is undeniable. In recent reports, exten-
sive analysis of single nucleotide polymorphisms (SNP)
has been used to produce high-resolution maps of break-
points at greater frequency identified by allele variant
population haplotype analysis. Some have argued that
allele variant segregation and population haplotype anal-
ysis is erratic, influenced by gene frequency and popula-
tion dynamics [23]. On the contrary, it is exactly these
properties that have allowed allele variant population
haplotype analysis to identify ethnic descent and migra-
tion of Homo sapiens so precisely.
LD analysis of SNP distribution in haplotypes defined by
maximum likelihood methods has revealed genomic
structures similar to and yet far less complex than those
identified by allele variants haplotyped by segregation
analysis [1-6,24]. The former method may be responsible
for some oversimplification of recent haplotype analyses
[1,4], but using SNP markers alone may also pose inher-
ent problems. High-throughput localization of SNP distri-
bution is inarguably efficient, but the vast majority ofBMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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SNPs reside outside coding regions. Although there is
potential for polymorphisms in non-coding promoter
and intron DNA to influence subsequent transcription
and splicing of a gene [25,26], selection pressure is more
likely to operate at the protein level. Particular haplotype
block combinations of relatively long genomic distance
are likely to have been initially fixed in response to geo-
graphical or environmental influences. The passage of
Comparison of SNPs between CEHs Figure 2
Comparison of SNPs between CEHs. A. Upper panel: Previously reported SNP distribution over the human MHC (NCBI 
dbSNP Build 126) indicating the higher density of SNPs in the HLA-A, Cw, B and HLA-DR/DQ regions. Across the indicated 
region (position 28,944,796 to 33,362,643; from ~1 Mb telomeric to HLA-A to ~0.2 Mb centromeric to HLA-DPB1), there is a 
mean frequency of ~790 SNP/50 kb genomic DNA. Lower panel: Distribution of SNPs incorporated into the Affymetrix Gene-
Chip Human Mapping 500 K array. The horizontal line represents the mean distribution in the region (~5 SNP/50 kb) and the 
vertical bar to the left of the line indicates one standard deviation. Thus, the chip uses only 0.6% (428 SNPs) of the SNPs 
reported in the region to date. Note that gene chip SNP representation in the regions harboring defined HLA polymorphic 
alleles is even lower. B. Top panel: SNP variations were determined between two cell lines (EM10 and FS10) homozygous for 
the CEH [HLA-A*2601, E*010301, Cw*1203, B*3801, SC21, DRB1*0402, DQA1*0301, DQB1*0302] except for EM10, which is 
heterozygous for HLA-E*0101 and HLA-E*010301. For all panels in this figure, a value of 0 indicates homozygous identity 
between the two cell lines, a value of 1 indicates heterozygosity for the SNP in at least one of the cell lines, and a value of 2 
indicates complete discordance between the two cell lines. Second panel: SNP variations between the B8HM1 and B8HM2 cell 
lines each homozygous for the CEH [HLA-A*0101, E*0101, Cw*0701, B*0801, SC01, DRB1*0301, DQB1*0201]. Third panel: A 
comparison of the homozygous SNP identities shared between EM10 and FS10 (the HLA-A*26, B*38 CEH) cell lines with the 
homozygous SNP identities shared between B8HM1 and B8HM2 (the HLA-A*01, B*08 CEH) cell lines. Only those SNPs for 
which there was an unequivocal call for all four cell lines were included. Fourth panel: SNP variations between the HLA-A*26, 
B*38 CEH and the L2DB cell line homozygous for the independent HLA-A*03, B*07 CEH ([HLA-A*0301, E*010302, Cw*0702, 
B*0702, SC31, DRB1*1501, DQA1*0102, DQB1*0602]. Bottom panel: SNP variations between the HLA-A*01, B*08 CEH and 
the L2DB cell line homozygous for the HLA-A*03, B*07 CEH.BMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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time, migration and alterations in climate and local flora
prevent analysis, but identification of other non-immune-
related haplotype blocks offers support for selection influ-
ence on haplotype structure [11]. However, a recent report
"mapping" the MHC using both HLA alleles and SNPs by
LD analysis of haplotypes defined by maximum likeli-
hood methods [24], suggests that the primary reason such
maps fail to detect the details of human population hap-
lotype structure [1-6] is their use of probabilistic (as
opposed to segregation) analysis.
Conclusion
The identified associations of HLA-E  alleles and SNPs
within established CEHs, increase the extent of their rec-
ognized fixity. For example, HLA-B*4403 distributes with
two CEH class I variants, (HLA-A*2301,  Cw*04xx,
B*4403) (with two HLA-Cw*04xx variants of its own) and
(HLA-A*2902,  Cw*1601,  B*4403) [27]. HLA-E  allele
identification improves the class I differentiation of these
CEHs to (HLA-A*2301, E*0101, Cw*04xx, B*4403) and
(HLA-A*2902,  E*010302,  Cw*1601,  B*4403), respec-
tively. Results of several recent studies on two specific
CEHs support our general conclusion of the fixity of CEHs
in the class I region. Both high density SNP [28] and rese-
quencing [29] analysis of the A1-B8-DR3 CEH and high
density SNP analysis of the A30-B18-DR3 CEH [30]
showed the essential sequence fixity of each of those hap-
lotypes in unrelated individuals. Here, in a more limited
set of samples, our high density SNP analysis confirms the
essential fixity of the CEH [HLA-A*26,  Cw*12,  B*38,
SC21, DRB1*04].
Since the SNP data so strongly support the genetic fixity of
CEHs first observed by direct allele analysis, several
approaches may be taken to improve haplotype defini-
tion. First, to define the SNP variants of particular CEHs,
the density of SNP analysis can be raised to almost com-
plete levels by choosing the limited subset expressed
within a predefined CEH. An alternate approach based on
the strong SNP support for CEHs, is to identify other pol-
ymorphic MHC genes, particularly in the HLA-A to HLA-
C region, for consideration in LD analysis. Therefore, we
identified several polymorphic markers within the 1.3 Mb
of genomic DNA between HLA-A and HLA-C (Fig. 3).
Analysis of these markers permits determination of hierar-
chical haplotype block associations where block variation
within the CEH may provide further insights into human
diversity and disease susceptibility. Determining the fre-
quency of sizes of DNA blocks in different populations
will add a new dimension in the studies of human diver-
sity and gene localization in diseases associated with the
MHC class I region [1]. In this latter instance, the high res-
olution allele analysis will lead to better definition of the
associative levels of MHC DNA blocks, CEHs and their
fragments influenced by genetic admixture allowing more
precise elucidation of disease-associated HLA alleles when
comparing different ethnic groups and nationalities.
Methods
Population
All participants either provided clinical samples prior to
hematopoietic cell transplantation or gave informed con-
sent for research purposes in accordance with the CBR
Institute for Biomedical Research (CBRI) or Dana-Farber
Cancer Institute (DFCI) Institutional Review Board-
approved protocols. The initial panel (Panel 1) was com-
posed of 216 healthy unrelated North American residents
typed for HLA-A, HLA-B and HLA-C, of which 56 were
homozygous for both HLA-A  and  HLA-B, 58 were
homozygous for HLA-B and heterozygous for HLA-A, and
102 were homozygous for HLA-A and heterozygous for
HLA-B. Panel 2 was composed of 176 unrelated parents of
88 Caucasian families. We assigned haplotypes by inher-
itance.
Panel 3 consisted of three groups of individuals enriched
in previously defined MHC CEHs or their markers. The
first group were unrelated subjects who provided samples
used to generate 25 International Histocompatibility
Workshop (IHW) and 5 locally produced cell lines. The
second subject group for this panel consisted of 130 sub-
jects in 49 unrelated families whose MHC haplotypes
were defined by segregation analysis. The third group con-
sisted of 31 unrelated subjects.
Cell lines
The EM10, FS10, B8HM1, B8HM2 and L2DB cell lines
were used to represent homozygous haplotypes in Figure
2, as described previously [31].
MHC typing
Genomic DNA was obtained from peripheral blood
mononuclear cells (PBMC), EDTA-treated plasma or lym-
phoblastoid cell lines and was isolated using the QIAamp
DNA mini kit (Qiagen, Valencia, CA). Molecular typing of
IHW cell lines was previously known [32] and/or was con-
ducted as described below. Molecular typing of samples
from Panels 1 and 2 was performed by PCR and sequence-
specific oligonucleotide probes (PCR-SSOP) at intermedi-
ate to high resolution [33]. SSP molecular typing of non-
IHW cell line samples from Panel 3 was performed either
using an SSP UniTray kit (Invitrogen/Dynal/Pel-Freez,
Brown Deer, WI) or by PCR-SSOP (HLA Quick-Type kits,
Lifecodes, Stamford, CT), according to previously
described amplification conditions [33]. Some samples
from the CBRI had several HLA types identified serologi-
cally [34]. Typing of BF, C4A and C4B alleles was done by
agarose gel electrophoresis and immunofixation of their
protein products with specific antisera, and C2  alleles
were determined by isoelectric focusing of serum samplesBMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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in polyacrylamide gels followed by a C2-sensitive hemo-
lytic overlay [35]. MHC complement gene haplotypes or
complotypes are designated by their BF, C2, C4A, and C4B
alleles, in that arbitrary order [7]. Null or Q0 alleles are
simply designated 0. Thus, FC31 indicates the complotype
BF*F, C2*C, C4A*3, C4B*1. Some of the non-HLA-E typ-
ings have been published previously [4,5,27].
HLA-E typing
Amplification – After extraction of genomic DNA, pub-
lished primers were used for the amplification of exons 2
and 3 of the HLA-E gene [36]. Amplification reactions
were carried out in 50 μl final volume containing 100 ng
of genomic DNA, 0.3 mM of each dNTP (Amersham Phar-
macia Biotech Inc.), 1× Buffer (Roche Molecular Bio-
Human MHC class I map showing known polymorphic genes Figure 3
Human MHC class I map showing known polymorphic genes. Distances are drawn to scale (see legend), but these 
may vary at many locations in different haplotypes as a result of limited polymorphic DNA insertions, deletions or gene dupli-
cations. Two non-classical polymorphic candidate genes (white text boxes), RNF39 (ring finger protein 39) and TRIM10 (tripar-
tite motif-containing 10), are located between the HLA-type genes (gray text boxes) HLA-A and HLA-E, while other 
polymorphic genes are located between HLA-E and HLA-C: CDSN (corneodesmosin), IER3 (immediate early response 3), MDC1 
(mediator of DNA damage checkpoint 1), PPP1R10 (protein phosphatase 1, regulatory inhibitor subunit 10) and GNL1 (guanine 
nucleotide binding protein-like 1). Gene locations are drawn to scale and were taken from the Sanger Institute MHC list for 
the COX cell line [41] and the distance (in megabases (Mb)) from HLA*B at the centromeric (C) end to an arbitrary point tel-
omeric (T) to HLA-A are shown.
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chemicals), 1.5 mM MgCl2, 1.25 units of Taq polymerase
(Roche) and 15 pmol of primers. PCR conditions were:
94°C denaturation for 5 min, followed by 35 cycles of
94°C for 1 min, 58°C (exon 2) or 60°C (exon 3) for 1
min, 72°C for 2 min, followed by a final extension step at
72°C for 10 min. Products were visualized by staining
with ethidium bromide on 1.8% agarose gels. We did not
amplify the region of exon 4 that would have distin-
guished HLA-E*010304 [14] from the other alleles. PCR-
SSOP – The alleles HLA-E*0101, E*010301, E*010302,
and E*0104 were assigned using a PCR-SSOP method as
described previously [37]. All the typings included those 4
known internal controls. Briefly, 3 μl of PCR products
were blotted onto nylon membranes and dried at room
temperature. Denaturation of the DNA on the mem-
branes was performed in constant gentle agitation with
0.4 M NaOH for 10 min and equilibrated in SSC for 5
min. Membranes were dried at room temperature and
then illuminated with a 254 nm ultraviolet lamp for 5
min to fix the nucleic acid. Pre-hybridization consisted of
incubation with 0.2 ml/cm2 of hybridization buffer (SSC,
1% Blocking Reagent (Roche), 1% N-lauryl sarcosine,
0.02% SDS) and left for 30 min at 42°C. Hybridization
was performed at 42°C for 3 hr using new hybridization
buffer (0.2 ml/cm2) containing oligonucleotides specific
for HLA-E previously labelled with dig-ddUTP (Roche)
[36] followed by two washes in SSPE, 0.1% SDS at room
temperature for 5 min each time, washing in 50 ml pre-
heated tetramethylammonium chloride/0.1% SDS solu-
tion (Lifecodes Corporation) at 59°C for 20 min and two
final washes 50 ml of 2 × SSPE at room temperature for 10
min each time. Membranes were equilibrated in buffer 1
(100 mM Tris-HCl, pH 7.2, 150 mM NaCl) for 5 min fol-
lowed by blocking in buffer 1 containing 2% blocking rea-
gent (Roche) for 1 hr followed by the detection agent,
anti-digoxigenin-AP antibody (75 mU/ml in buffer 1
(Roche) for 30 min. After washing two times in buffer 1
for 15 min each followed by buffer 2 (100 mM Tris-HCl
pH 9.5, 100 mM NaCl, 50 mM MgCl2) for 5 min, signal
was developed by placing wet membranes in pre-warmed
Lumiphos (Lifecodes) on acetate sheets, excess solution
was removed, and after incubation at 37°C for one hour,
the chemiluminescent signal was detected by film expo-
sure. PCR-RFLP – In a limited number (176) of subjects
representing all 3 subject panels, the PCR-RFLP method
was used to detect HLA-E*010303. Following amplifica-
tion of exon 3 as described above, the product was
digested with Bgl1 (New England Biolabs), separated on a
2.5% agarose gel and stained with ethidium bromide. The
presence of HLA-E*010303 was detected by the presence
of a specific 247 bp band and a separate 73 bp band, while
other alleles yielded bands at 135 bp and 112 bp and the
73 bp band.
HLA-E haplotype assignment
Panel 1 haplotypes were unambiguously assigned from
individuals homozygous for at least HLA-A and HLA-E (in
whom HLA-Cw, B blocks were assigned based on known
associations [1]) or homozygous for at least HLA-E and
HLA-Cw, B. Panel 2 haplotypes were assigned by family
study using segregation analysis [5]. For the third panel,
we assigned HLA-E alleles to 258 MHC haplotypes. Of
these, 167 haplotypes (65%) were unambiguously
assigned by one of four methods: a) in IHW or locally-
produced MHC homozygous cell lines; b) by segregation
analysis in pedigrees [5]; c) to previously defined (by seg-
regation analysis) haplotypes in subjects homozygous for
HLA-E; or d) to deduced haplotypes in subjects
homozygous for at least HLA-E  and their HLA-Cw, B
blocks. The cell lines (a, above) were assumed to be con-
sanguineous (and received only one haplotype assign-
ment) unless known not to be consanguineous. At the
end of this first analysis, we assigned HLA-E alleles to the
six most frequent CEHs (Table 3). The remaining haplo-
types (n = 91) were assigned HLA-E  alleles with two
assumptions. First, individuals who had all of the class I
to complotype markers of at least one CEH were included
in the analysis, and all of the markers of a given CEH were
assigned to one of the haplotypes. Second, for individuals
without clear HLA-E assignment (e.g., a family in which
all subjects were HLA-E heterozygous and identical or an
HLA-E heterozygous individual without relatives in the
study), but who had at least one haplotype with the class
I markers of one of the six CEHs defined above, the
defined HLA-E assignment was given to that CEH.
SNP analysis
Genomic DNA was digested with Nsp1 or Sty1 prior to
adapter ligation, amplification, end-labeling and hybridi-
zation to a GeneChip (GeneChip Human Mapping 500 K
Array Set; Affymetrix, Santa Clara, CA). Arrays were ana-
lyzed on a GeneChip Scanner 7000 RG and data analyzed
using the GTYPE software all according to the manufac-
turer's directions. 428 SNPs from the region from position
28,944,796 (near the gene TRIM27, approximately 1.0
Mb telomeric to HLA-A) to 33,362,643 (near the gene
B3GALT4, approximately 0.2 Mb centromeric to HLA-
DPB1) were analyzed (Genbank dbSNP build 126
rs209163 to rs466384). In several instances, a clear call on
the polymorphism could not be made in which case the
SNP was not used. Consequently, depending on the calls
for each cell line, approximately 370 SNP with high con-
fidence calls for each cell line were compared (Fig. 2B).
Statistical analysis
Allele frequencies of HLA generic and allele types were cal-
culated for each of the three panels separately by direct
counting [1-6]. LD for alleles at loci between HLA-E and
HLA-A or between HLA-C and HLA-B was analyzed inBMC Genetics 2007, 8:14 http://www.biomedcentral.com/1471-2156/8/14
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Panel 2 using delta (Δ) and normalized delta (D'). Other
two-point LD calculations were made between HLA-E and
the HLA-Cw/B block, with the latter analyzed as a single
entity, and between HLA-A and HLA-E/Cw/B, with the lat-
ter analyzed as a single entity. Although D' normalizes for
allele frequency, it does not compensate for sample size.
Accordingly, we used Fisher's exact test to provide an addi-
tional measure of significance of association of the loci.
We defined significant LD as positive normalized delta
(D') in the context of p < 0.05. LD is defined as a fre-
quency of possible association for specific alleles at two or
more loci (i.e., a putative haplotype) that departs from
expectation based on the known frequencies of the indi-
vidual alleles comprising that haplotype (determined in
this report by pedigree (i.e., genotypic data) analysis). In
a homogenous population at genetic equilibrium, if the
alleles A and B at two loci with frequencies f(A) and f(B),
respectively, are completely randomly associated with one
another, they form an AB haplotype with a frequency of
f(AB) = f(A) · f(B). If these conditions are not met, the
alleles are said to be "in LD." The extent of LD is given by
Δ = f(AB) - [f(A) · f(B)], in which larger delta (Δ) values
indicate greater LD. The LD of a two-locus haplotype, AiBj
will be:
LD (AiBj) = HF (AiBj) - aibj
where HF is the haplotype frequency and ai and bj, the fre-
quencies of Ai and Bj alleles [1]. The Δ value is converted
to a normalized LD value (D') to determine the relative
LD irrespective of individual allele frequencies. This nor-
malized value is calculated as:
D' = Δ/Δmax
where Δmax is the maximum LD value possible [38]. The
significance of all the results (Tables 1, 2, 3 and Figure 1)
was assessed with Fisher's exact test with Bonferroni cor-
rection [39]. Odds ratios (ORs) were calculated with a
95% CI [36].
MHC gene location and distances
Physical distances between MHC genes were found at the
Wellcome Trust Sanger Institute Human Chromosome 6
website [40].
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